You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

rc48-adc

Showing 1 - 23 of 23
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastric Cancer Trial in Beijing (RC48-ADC, Herceptin, Toripalimab)

Not yet recruiting
  • Gastric Cancer
  • RC48-ADC
  • +4 more
  • Beijing, China
    Beijing Cancer Hospital
Aug 7, 2023

Non-muscle Invasive Bladder Cancer Trial in Chengdu (RC48-ADC)

Not yet recruiting
  • Non-muscle Invasive Bladder Cancer
  • RC48-ADC
  • Chengdu, Sichuan, China
    West China Hospital
Aug 10, 2023

Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, AK104)

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Oct 6, 2023

NSCLC Trial in Shanghai (RC48-ADC, Pyrotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Feb 16, 2023

Advanced Gastroesophageal Adenocarcinoma Trial in Beijing (RC48-ADC, S-1)

Recruiting
  • Advanced Gastroesophageal Adenocarcinoma
  • Beijing, China
  • +2 more
Sep 14, 2022

Salivary Gland Tumors Trial in Beijing (RC48-ADC)

Recruiting
  • Salivary Gland Tumors
  • RC48-ADC
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 28, 2022

Biliary Tract Cancer Trial (RC48-ADC, Envafolimab)

Not yet recruiting
  • Biliary Tract Cancer
  • (no location specified)
Jun 9, 2022

Gastric Cancer Trial in Beijing (RC48-ADC, RC98-ADC)

Not yet recruiting
  • Gastric Cancer
  • Beijing, Beijing, China
    Remegen
Aug 21, 2022

Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, JS001)

Not yet recruiting
  • Muscle Invasive Bladder Carcinoma
  • Beijing, Beijing, China
  • +2 more
Apr 2, 2022

Urothelial Carcinoma, HER2-expressing Trial in Beijing (RC48-ADC, Toripalimab, Gemcitabine)

Not yet recruiting
  • Urothelial Carcinoma
  • HER2-expressing
  • RC48-ADC
  • +4 more
  • Beijing, Beijing, China
  • +1 more
Apr 2, 2022

Metastatic Breast Cancer Trial in Beijing, Langfang (RC48-ADC)

Recruiting
  • Metastatic Breast Cancer
  • RC48-ADC
  • Beijing, Beijing, China
  • +2 more
Apr 8, 2022

Gynecological Malignancy Trial in Beijing (RC48-ADC)

Recruiting
  • Gynecological Malignancy
  • RC48-ADC
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences Cancer Hospital
Jan 6, 2022

Melanoma, Stage II, HER2-positive, Advanced Melanoma Trial (RC48-ADC)

Not yet recruiting
  • Melanoma, Stage II
  • +2 more
  • RC48-ADC
  • (no location specified)
Nov 29, 2021

Breast Cancer Trial in Beijing (RC48-ADC, Paclitaxel Injection, Docetaxel Injection)

Recruiting
  • Breast Cancer
  • RC48-ADC
  • +4 more
  • Beijing, Beijing, China
    Oncology Hospital, Chinese Academy of Medical Sciences
Nov 24, 2021

Urothelial Carcinoma Trial in China (RC48-ADC)

Active, not recruiting
  • Urothelial Carcinoma
  • RC48-ADC
  • Hefei, Anhui, China
  • +7 more
Feb 20, 2022

Bladder Cancer Trial in Nanjing (RC48-ADC, Triplizumab)

Not yet recruiting
  • Bladder Cancer
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Aug 20, 2021

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma Trial in Beijing (RC48-ADC)

Completed
  • Gastric Cancer
  • HER2 Overexpressing Gastric Carcinoma
  • RC48-ADC
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jan 12, 2022

Urothelial Carcinoma Trial in Beijing (RC48-ADC)

Active, not recruiting
  • Urothelial Carcinoma
  • RC48-ADC
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Sep 14, 2021

Biliary Tract Cancer Trial in China (RC48-ADC)

Recruiting
  • Biliary Tract Cancer
  • RC48-ADC
  • Hefei, Anhui, China
  • +16 more
Sep 14, 2021

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma Trial in China (RC48-ADC, Paclitaxel injection, Irinotecan Hydrochloride

Recruiting
  • Gastric Cancer
  • HER2 Overexpressing Gastric Carcinoma
  • RC48-ADC
  • +3 more
  • Beijing, Beijing, China
  • +51 more
Jan 6, 2022

Solid Tumors Trial in Beijing (RC48-ADC)

Completed
  • Solid Tumors
  • RC48-ADC
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Jul 28, 2020

Breast Tumors, Breast Diseases, Capecitabine Trial in China (RC48-ADC, Lapatinib, Capecitabine)

Recruiting
  • Breast Neoplasms
  • +5 more
  • RC48-ADC
  • +2 more
  • Beijing, Beijing, China
  • +66 more
Feb 18, 2022

Urothelial Carcinoma, Advanced Cancer Trial in Beijing (RC48-ADC)

Completed
  • Urothelial Carcinoma
  • Advanced Cancer
  • RC48-ADC
  • Beijing, N/A = Not Applicable, China
  • +1 more
Aug 20, 2019